Stuart Paynter
Vermögen: 700 973 $ am 31.05.2026
Vermögen: 700 973 $ am 31.05.2026
Stuart Paynter currently works at Oxxon Therapeutics Ltd., as Director from 2017, Oxford Biomedica (UK) Ltd., as Secretary & Director, Ceres Power Holdings plc, as Chief Financial Officer & Director from 2024, and The Institute of Chartered Accountants in England & Wales, as Member.
Mr. Paynter also formerly worked at STERIS Ltd., as Finance Director-European Region from 2001 to 2007, Shire Pharmaceuticals Ltd., as Senior Director-Finance Business from 2007 to 2016, Oxford Biomedica Plc, as Chief Financial Officer & Director from 2017 to 2024, and De La Rue Plc, as Head-Finance Business Partnering from 2016 to 2021.
Mr. Paynter received his undergraduate degree from Imperial College London.
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
CERES POWER HOLDINGS PLC 0,02 % | 31.12.2025 | 47.682 ( 0,02 % ) | 542 785 $ | 31.05.2026 |
OXFORD BIOMEDICA PLC 0,02 % | 31.12.2024 | 18.687 ( 0,02 % ) | 158 188 $ | 31.05.2026 |
| Unternehmen | Position | Beginn |
|---|---|---|
| CERES POWER HOLDINGS PLC | Finanzdirektor/CFO | 01.10.2024 |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services Offers accountancy qualifications and world class business resources | Corporate Officer/Principal | - |
Oxford Biomedica (UK) Ltd.
Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Develops novel gene therapy products and treatment for cystic fibrosis | Direktor/Vorstandsmitglied | - |
Oxxon Therapeutics Ltd.
Oxxon Therapeutics Ltd. BiotechnologyHealth Technology Operates as a biotechnology company | Direktor/Vorstandsmitglied | 29.08.2017 |
| Unternehmen | Position | Ende |
|---|---|---|
| OXFORD BIOMEDICA PLC | Finanzdirektor/CFO | 02.09.2024 |
| DE LA RUE | Corporate Officer/Principal | 01.07.2021 |
Shire Pharmaceuticals Ltd.
Shire Pharmaceuticals Ltd. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Finanzdirektor/CFO | 01.02.2016 |
STERIS Ltd.
STERIS Ltd. Medical SpecialtiesHealth Technology Manufactures surgical and other medical supplies | Corporate Officer/Principal | 01.07.2007 |
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
| Private Unternehmen | 9 |
|---|---|
Ceres Power Holdings plc
Ceres Power Holdings plc Electronic Production EquipmentElectronic Technology Engages in development and commercialization of fuel cell technology | Electronic Technology |
STERIS Ltd.
STERIS Ltd. Medical SpecialtiesHealth Technology Manufactures surgical and other medical supplies | Health Technology |
De La Rue Plc
De La Rue Plc Commercial Printing/FormsCommercial Services Designs, manufactures and delivers bank notes and provide authentication software | Commercial Services |
Oxford Biomedica Plc
Oxford Biomedica Plc BiotechnologyHealth Technology Operates as a contract development and manufacturing organization which provides viral vectors to pharmaceutical and biotechnology clients in cell and gene therapy fields | Health Technology |
Imperial College London
Imperial College London Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Institute of Chartered Accountants in England & Wales
Institute of Chartered Accountants in England & Wales Miscellaneous Commercial ServicesCommercial Services Offers accountancy qualifications and world class business resources | Commercial Services |
Shire Pharmaceuticals Ltd.
Shire Pharmaceuticals Ltd. BiotechnologyHealth Technology Manufactures biopharmaceutical products | Health Technology |
Oxxon Therapeutics Ltd.
Oxxon Therapeutics Ltd. BiotechnologyHealth Technology Operates as a biotechnology company | Health Technology |
Oxford Biomedica (UK) Ltd.
Oxford Biomedica (UK) Ltd. BiotechnologyHealth Technology Develops novel gene therapy products and treatment for cystic fibrosis | Health Technology |
Bitte wählen Sie Ihre Ausgabe
Alle länderspezifischen Finanzinformationen